Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

Open access
Ludwig, Heinz, Terpos, Evangelos, van de Donk, Niels, Mateos, Maria-Victoria, Moreau, Philippe, Dimopoulos, Melitios-Athanasios, Delforge, Michel, Rodriguez-Otero, Paula, San-Miguel, Jesús, Yong, Kwee, Gay, Francesca, Einsele, Hermann, Mina, Roberto, Caers, Jo, Driessen, Christoph, Musto, Pellegrino, Zweegman, Sonja, Engelhardt, Monika, Cook, Gordon, Weisel, Katja, Broijl, Annemiek, Beksac, Meral, Bila, Jelena, Schjesvold, Fredrik, Cavo, Michele, Hajek, Roman, Touzeau, Cyrille, Boccadoro, Mario, Sonneveld, Pieter · 2023 · The Lancet Oncology

Abstract

T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, hypogammaglobulinaemia, and infections are common. This Policy Review presents a consensus from the European Myeloma Network on the prevention and management of these adverse events. Recommended measures include premedication, frequent assessing for symptoms and severity of cytokine release syndrome, step-up dosing for several BsAbs and some CAR T-cell therapies; corticosteroids; and tocilizumab in the case of cytokine release syndrome. Other anti-IL-6 drugs, high-dose corticosteroids, and anakinra might be considered in refractory cases. ICANS often arises concomitantly with cytokine release syndrome. Glucocorticosteroids in increasing doses are recommended if needed, as well as anakinra if the response is inadequate, and anticonvulsants if convulsions occur. Preventive measures against infections include antiviral and antibacterial drugs and administration of immunoglobulins. Treatment of infections and other complications is also addressed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(23)00159-6

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 203

Metadata

Authors
Ludwig, H., Terpos, E., van de Donk, N., Mateos, M.-V., Moreau, P., Dimopoulos, M.-A., Delforge, M., Rodriguez-Otero, P., San-Miguel, J., Yong, K., Gay, F., Einsele, H., Mina, R., Caers, J., Driessen, C., Musto, P., Zweegman, S., Engelhardt, M., Cook, G., Weisel, K., Broijl, A., Beksac, M., Bila, J., Schjesvold, F., Cavo, M., Hajek, R., Touzeau, C., Boccadoro, M., & Sonneveld, P.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2023-06
Volume
24
Issue
6
Pages
e255-e269
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4378800539
Cited by
203
References
15
FWCI
36.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. https://app.cochat.ai/papers/10.1016/s1470-2045(23)00159-6
The paper
Ludwig, H., Terpos, E., van de Donk, N., Mateos, M.-V., Moreau, P., Dimopoulos, M.-A., Delforge, M., Rodriguez-Otero, P., San-Miguel, J., Yong, K., Gay, F., Einsele, H., Mina, R., Caers, J., Driessen, C., Musto, P., Zweegman, S., Engelhardt, M., Cook, G., . . . Sonneveld, P. (2023). Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(23)00159-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.